Home
Work packages
WP1: Project, pipeline & stakeholder management
Purpose:
Provide governance, coordination, data management, and stakeholder engagement to maximise scientific progress and long-term impact.
Lead partner:
Lygature
Contributing partners:
University of Dundee, GSK, GSK R&D
Main deliverables:
- Project governance and pipeline management framework
- Stakeholder engagement and Target Product Profiles (TPPs)
- Communication, dissemination, exploitation and data management plans
WP2: Engineered antibacterial phage proteins
Purpose:
Develop engineered bacteriophage-derived proteins (lysins) as precision antibacterials against difficult-to-treat systemic and polymicrobial wound Gram-negative bacterial infections.
Lead partner:
GSK
Contributing partners:
GSK R&D, Obulytix BV, University of Copenhagen, Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA)
Main deliverables:
- Libraries of engineered lysins with novel modes of action
- Proof-of-concept efficacy in relevant infection models
- Preclinical candidate molecules ready for further development
WP3: Transposon sequencing (TnSeq) for target identification
Purpose:
Use advanced genome-wide screening to identify new antibacterial targets, particularly for bacteria that survive inside human cells.
Lead partner:
University of Dundee
Contributing partners:
GSK, GSK R&D, Quadram Institute
Main deliverables:
- Validated TnSeq pipelines for intracellular bacteria
- Identification of novel targets and chemical series
- A knowledge base for host–pathogen interactions
WP4: Targeted protein degradation
Purpose:
Apply protein degradation technologies (e.g. PROTACs) to target bacterial proteins that are inaccessible to conventional antibiotics.
Lead partner:
Francis Crick Institute
Contributing partners:
University of Dundee, GSK, GSK R&D, University of Manchester, TB Alliance
Main deliverables:
- Proof-of-concept targeted protein degradation in bacteria
- Lead molecules for tuberculosis and intracellular infections
- New degradation strategies for antimicrobial drug discovery
WP5: Nanofitin conjugates
Purpose:
Develop Nanofitin-based delivery systems to improve targeting, safety, and pharmacokinetics of antibacterial biologics.
Lead partner:
Affilogic
Main deliverables:
- Nanofitin conjugates for pathogen targeting and half-life extension
- Proof-of-concept delivery of antimicrobial peptides and lysins
- Validation of Nanofitins as a scalable delivery platform
WP6: Long-acting therapeutics (LAT)
Purpose:
Create long-acting formulations that improve drug exposure and patient adherence, particularly for diseases like tuberculosis.
Lead partner:
University of Liverpool
Contributing partner:
TB Alliance
Main deliverables:
- Long-acting injectable formulation candidates
- Preclinical pharmacokinetic proof-of-concept
- At least one LAT advanced toward preclinical candidate status